<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131767</url>
  </required_header>
  <id_info>
    <org_study_id>398/04</org_study_id>
    <nct_id>NCT01131767</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Naproxen Sodium 220 mg &amp; Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of Naproxen sodium 220 mg +&#xD;
      Pseudoephedrine Hydrochloride 120 mg Extended Release tablets of with Aleve Cold and Sinus in&#xD;
      healthy adult human subjects, under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open randomized, two treatment, two period, two sequence, single dose, crossover study of 26&#xD;
      healthy human adult subjects under fed conditions with a washout period of 27 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Naproxen Sodium &amp; Pseudoephedrine HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aleve Cold and Sinus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium &amp; Pseudoephedrine HCl</intervention_name>
    <description>Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets</description>
    <arm_group_label>Aleve Cold and Sinus</arm_group_label>
    <arm_group_label>Naproxen Sodium &amp; Pseudoephedrine HCl</arm_group_label>
    <other_name>Aleve Cold and Sinus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfill all of the following criteria to be considered for inclusion into&#xD;
        this study:&#xD;
&#xD;
          -  Subjects will provide written informed consent.&#xD;
&#xD;
          -  Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing&#xD;
             at least 50 kg.&#xD;
&#xD;
          -  Subjects must be within ±15% of ideal body weight in relation to height according to&#xD;
             Life Insurance Corporation of India height-weight chart for non- medical cases.&#xD;
&#xD;
          -  Subjects must be of normal health as determined by medical history and physical&#xD;
             examination performed within 21 days prior to the commencement of the study.&#xD;
&#xD;
          -  Have normal ECG, X-ray and vital signs.&#xD;
&#xD;
          -  Availability of subject for the entire study period and willingness to adhere to&#xD;
             protocol requirements as evidenced by written informed consent.&#xD;
&#xD;
        If subject is a female volunteer and&#xD;
&#xD;
          -  Is of child bearing potential practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condoms, foams,&#xD;
             jellies. diaphragm,intrauterine device (IUD), or abstinence.&#xD;
&#xD;
          -  Is postmenopausal for at least 1 year.&#xD;
&#xD;
          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy has been performed on the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subjects will be excluded under following conditions:&#xD;
&#xD;
        History or presence of significant:&#xD;
&#xD;
          -  Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,&#xD;
             endocrine,immunologic, dermatologic, musculoskeletal, neurological or psychiatric&#xD;
             disease.&#xD;
&#xD;
          -  Alcohol dependence, alcohol abuse or drug abuse within past one year.&#xD;
&#xD;
          -  Moderate to heavy smoking (&gt;10 cigarettes/day) or consumption of tobacco products.&#xD;
&#xD;
          -  Asthma, urticaria or other allergic type reactions after taking any medication.&#xD;
&#xD;
        Subjects who through completion of the study, would have donated in excess of&#xD;
&#xD;
          -  500 ml of blood in 14 days, or&#xD;
&#xD;
          -  500 - 800ml of blood in 14 days (unless approved by the Principal Investigator)&#xD;
&#xD;
          -  1000 ml of blood in 90 days&#xD;
&#xD;
          -  1250 ml of blood in 120 days&#xD;
&#xD;
          -  1500 ml of blood in 180 days&#xD;
&#xD;
          -  2000 ml of blood in 270 days&#xD;
&#xD;
          -  2500 ml of blood in 1 year&#xD;
&#xD;
        Subjects who have participated in another clinical trial within 3 months of study start.&#xD;
&#xD;
        Subjects who have:&#xD;
&#xD;
          -  Systolic blood pressure less than 90 mm of Hg and higher than 150 mm of Hg&#xD;
&#xD;
          -  Diastolic blood pressure less than 60 mm of Hg and more than 95 mm of Hg. Minor&#xD;
             deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the&#xD;
             physician/investigator.&#xD;
&#xD;
          -  Pulse rate below 50/min. and above 105/min. Female volunteers demonstrating a positive&#xD;
             pregnancy screen or currently breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandhya Ravi, MBBS, MS.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Labs Pvt. Ltd.,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Labs Private Limited</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>M.S. Mohan / Vice President, R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Naproxen Sodium and Pseudoephedrine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

